株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

神経疾患治療薬市場:疾患別 (てんかん、パーキンソン病、アルツハイマー病、多発性硬化症、脳血管疾患)、薬剤タイプ別) - 欧州の業界分析、規模、シェア、成長、動向、および予測

Neurological Disorder Drugs Market (Disorder - Epilepsy, Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Cerebrovascular Disease; Drug Type) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

発行 Transparency Market Research 商品コード 410942
出版日 ページ情報 英文 224 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
神経疾患治療薬市場:疾患別 (てんかん、パーキンソン病、アルツハイマー病、多発性硬化症、脳血管疾患)、薬剤タイプ別) - 欧州の業界分析、規模、シェア、成長、動向、および予測 Neurological Disorder Drugs Market (Disorder - Epilepsy, Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Cerebrovascular Disease; Drug Type) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
出版日: 2016年12月16日 ページ情報: 英文 224 Pages
概要

当レポートでは、欧州の神経疾患治療薬市場について調査し、市場の動向、疾患別、薬剤タイプ別、国別動向、および市場に参入する主要企業のプロファイルなどをまとめています。

第1章 序論

第2章 市場概要

  • エグゼクティブサマリー
  • 市場スナップショット

第3章 市場動向

  • 促進因子と阻害因子分析
  • 促進因子
    • 高齢化による神経疾患の増加
    • 治療の拡大
    • 政府機関による介入
    • 研究開発プログラムの増加
    • 神経系薬剤への投資が途上国で拡大
    • 認知度の向上
  • 阻害因子
    • 高い治療費
    • 厳しい法規制
  • 機会
    • 技術進歩と革新
    • 新興市場における重要な範囲

第4章 市場概要

  • 市場収益予測
  • 疾患概要と疫学
    • 筋ジストロフィー
    • 多発性硬化症
    • パーキンソン病
    • 切断手術患者
  • 国別疾患頻度
  • 将来見通し
  • 年齢別標的人口
  • アルツハイマー病:罹患率
  • 生活条件
  • 市場見通し

第5章 疾患別市場分析

  • イントロダクション
  • 市場価値シェアおよび魅力度分析
  • 市場予測
    • てんかん
    • アルツハイマー病
    • パーキンソン病
    • 多発性硬化症
    • 脳血管疾患
    • その他

第6章 薬剤タイプ別市場分析

  • イントロダクション
  • 市場価値シェアおよび魅力度分析
  • 市場予測
    • 抗コリン剤
    • 抗てんかん剤
    • 抗精神病薬
    • 鎮痛剤
    • 睡眠剤
    • 抗高血圧剤
    • 抗凝固剤
    • その他

第7章 流通チャネル別市場分析と予測

  • イントロダクション
  • 市場価値シェアおよび魅力度分析
  • 市場予測
    • 院内薬局
    • 小売薬局
    • Eコマース

第8章 国別市場分析と予測

第9章 ドイツ市場

第10章 英国市場

第11章 フランス市場

第12章 イタリア市場

第13章 スペイン市場

第14章 ロシア市場

第15章 オランダ市場

第16章 スイス市場

第17章 ポーランド市場

第18章 その他の欧州諸国市場

第19章 企業プロファイル

  • 企業別市場シェア分析
  • 企業プロファイル
    • Novartis AG
    • GlaxoSmithKline plc
    • Merck & Co.
    • Bayer AG
    • AstraZeneca
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
目次

Title: Neurological Disorder Drugs Market (Disorder - Epilepsy, Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, and Cerebrovascular Disease; Drug Type - Anticholinergic, Antiepileptic, Antipsychotic, Analgesics, Hypnotic & Sedative, Antihypertensive, and Anticoagulants; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and eCommerce) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.

dEurope Neurological Disorder Drugs Market: Overview

This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related to life threatening diseases are the major concerns in the developed and developing countries of Europe.

This research report provides a detailed analysis of the neurological disorder drugs market and helps understand the various driving factors for the growth of the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. Market dynamics factors such as market attractiveness analysis have also been explained in order to deliver a thorough analysis of the overall competitive scenario of the Europe neurological disorder drugs market.

Europe Neurological Disorder Drugs Market: Segmentation

The neurological disorder drugs market has been segmented by disorder, by drug class, by distribution channel and by countries. The disorder segment has been sub-segmented into Epilepsy, Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, Cerebrovascular disease and others. The drug class has been segmented into Anticholinergic, Antiepileptic, Antipsychotic, Analgesics, Hypnotic & Sedative, Antihypertensive, Anticoagulants and others. The distribution channel segment has been sub-segments into retail pharmacy, hospital pharmacy and eCommerce.

Europe Neurological Disorder Drugs Market: Scope

The executive summary provides detailed insights about the report and the market in general. This elaborate executive summary provides a glimpse into the present scenario of the Europe neurological disorder drugs market, which includes a market snapshot that provides overall information of various segments and sub-segments. The executive summary also provides overall information and data analysis of the Europe neurological disorder drugs market with respect to market segments based on disorder, drug class, distribution channel as well as geographic regions.

The market for neurological disorder drugs has been extensively analyzed based on their usefulness, effectiveness, sales revenue and geographic presence. The market size and forecast in terms of US$ Mn for each disorder, drug class, distribution channel as well as geographic regions has been provided for the period from 2016 to 2024. This report on the neurological disorder drugs market also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year.

Europe Neurological Disorder Drugs Market: Regional Outlook

Geographically, the neurological disorder drugs market has been segmented into 10 major regions: Germany, France, Italy, Spain, U.K., Russia, Switzerland, Netherlands, Poland and Rest of Europe. The market size and forecast for each of these regions have been provided for the period from 2016 to 2024, along with CAGR (%) for the forecast period from 2016 to 2024. The research study also incorporates the competitive scenario in these regions.

Key Players Mentioned in this Report are:

A list of recommendations has been provided for new entrants as well as existing players to help establish a strong presence in the market and increase market share. The report also profiles major players in the neurological disorder drugs market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, and GlaxoSmithKline plc.

The Europe Neurological Disorder Drugs market is segmented as follows:

Europe Neurological Disorder Drugs Market Revenue, by Disorder

  • Epilepsy
  • Alzheimer's disease
  • Parkinson's disease
  • Multiple Sclerosis
  • Cerebrovascular disease
  • Others

Europe Neurological Disorder Drugs Market Revenue, by Drug Class

  • Anticholinergic
  • Antiepileptic
  • Antipsychotic
  • Hypnotic & Sedative
  • Analgesics
  • Antihypertensive
  • Anticoagulants
  • Others

Europe Neurological Disorder Drugs Market Revenue, by Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • eCommerce

Europe Neurological Disorder Drugs Market Revenue, by Geography

  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Russia
  • Switzerland
  • Netherlands
  • Poland
  • Rest of Europe

Table of Contents

Section 1: Preface

  • 1.1. Report Scope and Market Segmentation
  • 1.2. Assumptions and Acronyms Used
  • 1.3. Research Methodology

Section 2: Market Overview

  • 2.1. Executive Summary
  • 2.2. Market Snapshot

Section 3: Market Dynamics

  • 3.1. Drivers and Restraints Snapshot Analysis
  • 3.2. Drivers
    • 3.2.1. Aging population leading to increase neurological disorders
    • 3.2.2. Increasing Therapeutic Treatments
    • 3.2.3. Rise in interventions by government bodies
    • 3.2.4. Rising Research & Development Programmes
    • 3.2.5. Spending on neurological drugs to grow in developing countries
    • 3.2.6. Growing awareness among people
  • 3.3. Restraints
    • 3.3.1. High treatment cost
    • 3.3.2. Stringent regulations
  • 3.4. Opportunities
    • 3.5.1. Technological Advancement and Innovation
    • 3.5.2. Significant Scope in Emerging Markets

Section 4: Market Overview

  • 4.1. Europe Neurological Disorder Drugs Market Analysis and Forecasts, Market Revenue Projections (US$ Mn)
  • 4.2. Disease description and epidemiology
    • 4.2.1. Muscle Dystrophy
    • 4.2.2. Multiple Sclerosis
    • 4.2.3. Parkinson Disease
    • 4.2.4. Amputees
  • 4.3. Disease Frequency by Country
  • 4.4. Future Outlook
  • 4.5. Target population by Age Group
  • 4.6. Alzheimer Disease - Prevalence Rate
  • 4.7. Living Conditions
  • 4.8. Neurological Disorder Drugs Market Outlook

Section 5: Europe Neurological Disorder Drugs Market Analysis, by Disorder

  • 5.1. Introduction
  • 5.2. Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Disorder
  • 5.3. Europe Neurological Disorder Drugs Market Forecast, by Disorder
    • 5.3.1. Epilepsy
    • 5.3.2. Alzheimer's Disease
    • 5.3.3. Parkinson Disease
    • 5.3.4. Multiple Sclerosis
    • 5.3.5. Cerebrovascular Disease
    • 5.3.6. Others

Section 6: Europe Neurological Disorder Drugs Market Analysis, by Drug Type

  • 6.1. Introduction
  • 6.2. Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Drug Type
  • 6.3. Europe Neurological Disorder Drugs Market Forecast, by Drug Type
    • 6.3.1. Anticholinergic
    • 6.3.2. Antiepileptic
    • 6.3.3. Antipsychotic
    • 6.3.4. Analgesics
    • 6.3.5. Hypnotic & Sedative
    • 6.3.6. Antihypertensive
    • 6.3.7. Anticoagulants
    • 6.3.8. Others

Section 7: Europe Neurological Disorder Drugs Market Analysis, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Distribution Channel
  • 7.3. Europe Neurological Disorder Drugs Market Forecast, by Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. eCommerce

Section 8: Europe Neurological Disorder Drugs Market Analysis By Country

  • 8.1. Neurological Disorder Drugs Market Forecast, By Country

Section 9: Germany Neurological Disorder Drugs Market Analysis

  • 9.1. Germany Neurological Disorder Drugs Market Overview
  • 9.2. Germany Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 9.3. Germany Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 9.4. Disease description and epidemiology
    • 9.4.1. Muscular Dystrophy
    • 9.4.2. Multiple Sclerosis
    • 9.4.3. Parkinson's Disease
    • 9.4.4. Amputees
  • 9.5. Disease Frequency by Country
  • 9.6. Target population by Age Group
  • 9.7. Alzheimer's Disease - Prevalence Rate
  • 9.8. Living Conditions

Section 10: UK Neurological Disorder Drugs Market Analysis

  • 10.1. UK Neurological Disorder Drugs Market Overview
  • 10.2. UK Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 10.3. UK Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 10.4. Disease description and epidemiology
    • 10.4.1. Muscular Dystrophy
    • 10.4.2. Multiple Sclerosis
    • 10.4.3. Parkinson's Disease
    • 10.4.4. Amputees
    • 10.4.5. Disease Cost
  • 10.5. Target population by Age Group
  • 10.6. Alzheimer's Disease - Prevalence Rate
  • 10.7. Living Conditions

Section 11: France Neurological Disorder Drugs Market Analysis

  • 11.1. France Neurological Disorder Drugs Market Overview
  • 11.2. France Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 11.3. France Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 11.4. Disease description and epidemiology
    • 11.4.1. Muscular Dystrophy
    • 11.4.2. Multiple Sclerosis
    • 11.4.3. Factors Associated with Increased Risk for Multiple Sclerosis
    • 11.4.4. Parkinson's Disease
    • 11.4.5. Amputees
  • 11.5. Disease Cost
  • 11.6. Target population by Age Group
  • 11.7. Alzheimer's Disease - Prevalence Rate
  • 11.8. Living Conditions

Section 12: Italy Neurological Disorder Drugs Market Analysis

  • 12.1. Italy Neurological Disorder Drugs Market Overview
  • 12.2. Italy Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 12.3. Italy Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 12.4. Disease description and epidemiology
    • 12.4.1. Muscular Dystrophy
    • 12.4.2. Multiple Sclerosis
    • 12.4.3. Parkinson's Disease
    • 12.4.4. Amputees
  • 12.5. Disease Frequency
  • 12.6. Target population by Age Group
  • 12.7. Alzheimer's Disease - Prevalence Rate
  • 12.8. Disability - Targeted Age Group
  • 12.9. Living Conditions

Section 13: Spain Neurological Disorder Drugs Market Analysis

  • 13.1. Spain Neurological Disorder Drugs Market Overview
  • 13.2. Spain Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 13.3. Spain Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 13.4. Disease description and epidemiology
    • 13.4.1. Muscular Dystrophy
    • 13.4.2. Multiple Sclerosis
    • 13.4.3. Parkinson's Disease
    • 13.4.4. Amputees
  • 13.5. Target population by Age Group
  • 13.6. Alzheimer's Disease - Targeted Age Group
  • 13.7. Living Conditions

Section 14: Russia Neurological Disorder Drugs Market Analysis

  • 14.1. Russia Neurological Disorder Drugs Market Overview
  • 14.2. Russia Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 14.3. Russia Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 14.4. Disease description and epidemiology
    • 14.4.1. Muscular Dystrophy
    • 14.4.2. Multiple Sclerosis
    • 14.4.3. Parkinson's Disease
    • 14.4.4. Amputees
  • 14.5. Target population by Age Group
  • 14.6. Living Conditions

Section 15: Netherlands Neurological Disorder Drugs Market Analysis

  • 15.1. Netherlands Neurological Disorder Drugs Market Overview
  • 15.2. Netherlands Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 15.3. Netherlands Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 15.4. Disease description and epidemiology
    • 15.4.1. Muscular Dystrophy
    • 15.4.2. Multiple Sclerosis
    • 15.4.3. Parkinson's Disease
    • 15.4.4. Amputees
  • 15.5. Disease Cost
  • 15.6. Target population by Age Group
  • 15.7. Alzheimer's Disease - Prevalence Rate
  • 15.8. Living Conditions

Section 16: Switzerland Neurological Disorder Drugs Market Analysis

  • 16.1. Switzerland Neurological Disorder Drugs Market Overview
  • 16.2. Switzerland Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 16.3. Switzerland Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 16.4. Disease description and epidemiology
    • 16.4.1. Muscular Dystrophy
    • 16.4.2. Multiple Sclerosis
    • 16.4.3. Parkinson's Disease
    • 16.4.4. Amputees
  • 16.5. Disease Cost
  • 16.6. Target population by Age Group
  • 16.7. Alzheimer's Disease - Prevalence Rate
  • 16.8. Living Conditions

Section 17: Poland Neurological Disorder Drugs Market Analysis

  • 17.1. Poland Neurological Disorder Drugs Market Overview
  • 17.2. Poland Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 17.3. Poland Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 17.4. Disease description and epidemiology
    • 17.4.1. Muscular Dystrophy
    • 17.4.2. Multiple Sclerosis
    • 17.4.3. Parkinson's Disease
    • 17.4.4. Amputees
  • 17.5. Target population by Age Group
  • 17.6. Alzheimer's Disease - Targeted Age Group
  • 17.7. Alzheimer's Disease - Prevalence Rate
  • 17.8. Living Conditions

Section 18: Rest of Europe Neurological Disorder Drugs Market Analysis

  • 18.1. Rest of Europe Neurological Disorder Drugs Market Overview
  • 18.2. Rest of Europe Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
  • 18.3. Rest of Europe Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
  • 18.4. Disease description and epidemiology
    • 18.4.1. Muscular Dystrophy
    • 18.4.2. Multiple Sclerosis
    • 18.4.3. Parkinson's Disease
    • 18.4.4. Amputees
  • 18.5. Alzheimer's Disease - Prevalence Rate
  • 18.6. Living Conditions

Section 19: Company Profiles

  • 19.1. Neurological Disorder Drugs Market Share Analysis, by Company (2015)
  • 19.2. Company profiles
    • 19.2.1. Novartis AG
      • 19.2.1.1. Company Overview
      • 19.2.1.2. Business Overview
      • 19.2.1.3. Financial Overview
      • 19.2.1.4. SWOT Analysis
      • 19.2.1.5. Strategic Overview
    • 19.2.2. GlaxoSmithKline plc
      • 19.2.2.1. Company Overview
      • 19.2.2.2. Business Overview
      • 19.2.2.3. Financial Overview
      • 19.2.2.4. SWOT Analysis
      • 19.2.2.5. Strategic Overview
    • 19.2.3. Merck & Co.
      • 19.2.3.1. Company Overview
      • 19.2.3.2. Business Overview
      • 19.2.3.3. Financial Overview
      • 19.2.3.4. SWOT Analysis
      • 19.2.3.5. Strategic Overview
    • 19.2.4. Bayer AG
      • 19.2.4.1. Company Overview
      • 19.2.4.2. Business Overview
      • 19.2.4.3. Financial Overview
      • 19.2.4.4. SWOT Analysis
      • 19.2.4.5. Strategic Overview
    • 19.2.5. AstraZeneca
      • 19.2.5.1. Company Overview
      • 19.2.5.2. Business Overview
      • 19.2.5.3. Financial Overview
      • 19.2.5.4. SWOT Analysis
      • 19.2.5.5. Strategic Overview
    • 19.2.6. Boehringer Ingelheim GmbH
      • 19.2.6.1. Company Overview
      • 19.2.6.2. Business Overview
      • 19.2.6.3. Financial Overview
      • 19.2.6.4. SWOT Analysis
      • 19.2.6.5. Strategic Overview
    • 19.2.7. Teva Pharmaceutical Industries Ltd.
      • 19.2.7.1. Company Overview
      • 19.2.7.2. Business Overview
      • 19.2.7.3. Financial Overview
      • 19.2.7.4. SWOT Analysis
      • 19.2.7.5. Strategic Overview
    • 19.2.8. F. Hoffmann-La Roche Ltd.
      • 19.2.8.1. Company Overview
      • 19.2.8.2. Business Overview
      • 19.2.8.3. Financial Overview
      • 19.2.8.4. SWOT Analysis
      • 19.2.8.5. Strategic Overview

List of Figures

  • Figure 01: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2015-2024
  • Figure 02: Europe Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 03: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2015
  • Figure 04: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 05: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 06: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 07: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 08: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 09: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 10: Europe Neurological Disorder Drugs Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 11: Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Type
  • Figure 12: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 13: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 14: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 15: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 16: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 17: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 18: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 19: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 20: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 21: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2024
  • Figure 22: Europe Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 23: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution channel, 2015
  • Figure 24: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2014-2024
  • Figure 25: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2014-2024
  • Figure 26: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2014-2024
  • Figure 27: Europe Neurological Disorder Drugs Market Value Share Analysis, by Country Type, 2016 and 2024
  • Figure 28: Neurological Disorder Drugs Market Attractiveness Analysis, by Region Type
  • Figure 29: Germany Neurological Disorder Drugs Market Size
  • Figure 30: Germany Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015-2024
  • Figure 31: Germany Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 32: Germany Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 33: Germany Market Value Share Analysis, by Distribution channel, 2016 and 2024
  • Figure 34: U.K. Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 35: U.K. Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015-2024
  • Figure 36: U.K. Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 37: U.K. Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 38: U.K. Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 39: France Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 40: France Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015-2024
  • Figure 41: France Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 42: France Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 43: France Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 44: Italy Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 45: Italy Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015-2024
  • Figure 46: Italy Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 47: Italy Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 48: Italy Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 49: Spain Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 50: Spain Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015-2024
  • Figure 51: Spain Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 52: Spain Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 53: Spain Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 54: Russia Neurological Disorder Drugs Market Size
  • Figure 55: Russia Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015-2024
  • Figure 56: Russia Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 57: Russia Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 58: Russia Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 59: Netherlands Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 60: Netherlands Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015-2024
  • Figure 61: Netherlands Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 62: Netherlands Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 63: Netherlands Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 64: Switzerland Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 65: Switzerland Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015-2024
  • Figure 66: Switzerland Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 67: Switzerland Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 68: Switzerland Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 69: Poland Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 70: Poland Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015-2024
  • Figure 71: Poland Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 72: Poland Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 73: Poland Market Value Share Analysis, by Distribution Channel, 2016 and 2024
  • Figure 74: Rest of Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014-2024
  • Figure 75: Rest of Europe Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015-2024
  • Figure 76: Rest of Europe Market Value Share Analysis, by Disorder, 2016 and 2024
  • Figure 77: Rest of Europe Market Value Share Analysis, by Drug Type, 2016 and 2024
  • Figure 78: Rest of Europe Market Value Share Analysis, by Distribution Channel, 2016 and 2024

List of Tables

  • Table 01: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Disorder, 2014-2024
  • Table 02: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2014-2024
  • Table 03: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014-2024
  • Table 04: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Country, 2014-2024
Back to Top